Financial Architects (New Jersey)’s Celldex Therapeutics CLDX Stock Holding History

Financial Architects (New Jersey)’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-149	Closed	-$1K	–	1234
2019 Q1	$1K	Sell	149 -1	-0.7%	-$5	﹤0.01%	1357
2018 Q4	$0	Sell	150 -60	-29%	-$295	﹤0.01%	1354
2018 Q3	$1K	Hold	210	–	–	﹤0.01%	1357
2018 Q2	$2K	Sell	210 -20	-9%	-$267	﹤0.01%	1205
2018 Q1	$8K	Hold	230	–	–	﹤0.01%	1140
2017 Q4	$10K	Hold	230	–	–	﹤0.01%	1147
2017 Q3	$10K	Buy	230 +40	+21%	+$1.5K	﹤0.01%	1118
2017 Q2	$7K	Buy	190 +14	+8%	+$619	﹤0.01%	1204
2017 Q1	$10K	Buy	176 +96	+120%	+$5K	﹤0.01%	1131
2016 Q4	$4K	Buy	80 +20	+33%	+$1.14K	﹤0.01%	1177
2016 Q3	$4K	Hold	60	–	–	﹤0.01%	1184
2016 Q2	$4K	Buy	+60	New	+$3.81K	﹤0.01%	1161

Other funds holding CLDX

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

CAM

Cresset Asset Management Chicago, Illinois $27.6B AUM 31.92% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

TCMG

TSP Capital Management Group Summit, New Jersey $418M AUM 68.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Financial Architects (New Jersey)'s CLDX Position: Q2 2019 in Review

Financial Architects (New Jersey) sold out of Celldex Therapeutics (CLDX) in Q2 2019, closing a stake of 149 shares — an estimated $1K sold.

Financial Architects (New Jersey) first reported a position in CLDX in Q2 2016 and held it in 12 quarters. The position peaked at $10K in Q4 2017. 51 funds tracked by Wall St. Rank hold CLDX as of Q2 2019.

Financial Architects (New Jersey) reported no remaining Celldex Therapeutics position as of Q2 2019 after selling out during the quarter.
Financial Architects (New Jersey) sold 149 Celldex Therapeutics shares in Q2 2019, an estimated $1K.
Financial Architects (New Jersey) first reported a position in Celldex Therapeutics in Q2 2016 and held it in 12 quarters.
Financial Architects (New Jersey)'s Celldex Therapeutics position peaked at $10K in Q4 2017.
51 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2019.

Based on Financial Architects (New Jersey)'s 13F filing for Q2 2019, filed 14 Aug 2019.